Skip to content
The announcement of “maximum fair prices” for the first 10 medicines targeted under the Inflation Reduction Act (IRA) has renewed questions and concerns about […]
The economics of the Inflation Reduction Act’s impact on innovation Read More »
The Inflation Reduction Act (IRA) has already begun to shift the way that innovative companies are investing in future breakthroughs. Over the past few
The Federal Trade Commission will host an open meeting this morning, and fortunately, drug middlemen are on the agenda. The meeting will review the findings
FTC to air grievances with PBMs’ abusive practices Read More »
In implementing the Inflation Reduction Act (IRA), the Centers for Medicare and Medicaid Services (CMS) has made efforts to unnecessarily broaden the law with
CMS overreach will impede innovation Read More »
Is the accelerated approval pathway helping patients achieve better health outcomes or imposing on society medicines that don’t work? In BIO’s view, the pathway
Setting the record straight on accelerated approval Read More »
Sen. Bernie Sanders (I-Vt.), Chair of the Senate Health, Education, Labor, and Pensions Committee, announced that he is launching an investigation into the pricing
The Inflation Reduction Act (IRA) is expected to have broad negative impacts on patients, most notably through less access to future cures and treatments.
Heart disease patients and the IRA’s misguided incentives Read More »
President Biden delivered his third State of the Union address last night, March 7. Health care was a prominent theme throughout the night, which
Key takeaways from the State of the Union address Read More »
On Monday, March 4, the White House will host a “listening session” on the impact of Pharmacy Benefit Managers (PBMs). This is a welcome
As White House prepares ‘listening session’ on PBMs, here’s what they need to hear Read More »
